Desloratadine/pseudoephedrine

Desloratadine/pseudoephedrine
Combination of
DesloratadineAntihistamine
PseudoephedrineAlpha-adrenergic agonist
Clinical data
Trade namesClarinex-D, Aerinaze
AHFS/Drugs.comMicromedex Detailed Consumer Information
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • US: ℞-only [1]
  • EU: Rx-only [2]
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
KEGG

Desloratadine/pseudoephedrine, sold under the brand name Clarinex-D among others, is a medication used for the treatment of seasonal allergic rhinitis.[1][2]

Desloratadine/pseudoephedrine was approved for use in the United States in 2005[1][3] and in the European Union in July 2007.[2]

Medical uses

Desloratadine/pseudoephedrine is indicated for the symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion.[2]

References

  1. 1 2 3 "Clarinex-D 12 Hour- desloratadine and pseudoephedrine sulfate tablet, extended release". DailyMed. 15 March 2019. Retrieved 1 March 2020.
  2. 1 2 3 4 "Aerinaze EPAR". European Medicines Agency. Retrieved 1 March 2020.
  3. ↑ "Drug Approval Package: Clarinex-D 24 Hour (Desloratadine/Pseudoephedrine Sulfate) NDA #021605". U.S. Food and Drug Administration (FDA). 9 May 2007. Retrieved 1 March 2020.

Further reading

  • Anolik R (June 2009). "Desloratadine and pseudoephedrine combination therapy as a comprehensive treatment for allergic rhinitis and nasal congestion". Expert Opin Drug Metab Toxicol. 5 (6): 683–94. doi:10.1517/17425250902980187. PMID 19473112. S2CID 22633518.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.